1 Analysis of cell-specific peripheral blood biomarkers in

2 severe allergic asthma identifies innate immune

3 dysfunction

- Ben Nicholas¹, Jane Guo², Hyun-Hee Lee², Alistair Bailey³, Rene de Waal Malefyt⁴,
 Milenko Cicmil² and Ratko Djukanovic¹
- ¹ Division of Clinical and Experimental Sciences, University of Southampton Faculty
 of Medicine, Southampton General Hospital, Hampshire, United Kingdom
- ² Oncology & Immunology Discovery, Merck Research Laboratories, Boston, MA,
 United States of America
- ³ Cancer Sciences, University of Southampton Faculty of Medicine, Southampton
 General Hospital, Hampshire, United Kingdom
- 12 ⁴ Merck Research Laboratories, Palo Alto, California, United States of America

13 **ORCIDs**:

- 14 Ben Nicholas: 0000-0003-1467-9643
- 15 Jane Guo:
- 16 Hyun-Hee Lee:
- 17 Alistair Bailey: 0000-0003-0023-8679
- 18 Rene de Waal Malefyt: 0000-0002-2663-383X
- 19 Milenko Cicmil:
- 20 Ratko Djukanovic: 0000-0001-6039-5612
- 21
- 22 Running title: Peripheral blood biomarkers of severe asthma
- 23 Keywords: Asthma, biomarkers, allergy, peripheral, transcriptomic
- 24 **Correspondence to:**
- 25 Dr Ben Nicholas
- 26 Centre for Proteomic Research
- 27 B85, Life Sciences Building
- 28 University of Southampton
- 29 University Road
- 30 Highfield
- 31 Southampton, Hants.
- 32 SO17 1BJ
- 33 Tel No: +44(0)2380 59 5503
- 34 Email: bln1@soton.ac.uk

35 Abstract

36	Asthma is a disease of complex origin and multiple pathologies. There are currently
37	very few biomarkers of proven utility in its diagnosis, management or response to
38	treatment. Recent studies have identified multiple asthma phenotypes following
39	biofluid analysis; however, such findings may be driven by the well-characterised
40	alterations in immune cell populations in asthma. We present a study designed to
41	identify cell type-specific gene signatures of severe allergic asthma in peripheral
42	blood samples. Using transcriptomic profiling of four magnetically purified peripheral
43	blood cell types, we identify significant gene expression changes in monocytes and
44	NK cells but not T lymphocytes in severe asthmatics. Pathway analysis indicates
45	dysfunction of immune cell regulation and bacterial suppression in the NK cells.
46	These gene expression changes may be useful on their own as prognostic
47	peripheral blood cell markers of severe asthma, but also may indicate novel cell
48	pathways for therapeutic intervention.

49 Asthma is a common chronic airways disease with complex aetiology, having no 50 single causative genetic trigger, and with multiple factors appearing to contribute to 51 disease pathogenesis¹. Thus, asthma can manifest in numerous different 52 pathologies related to severity and the degree of allergy or response to therapeutic 53 intervention. Currently, the principal clinical biomarkers for initial diagnosis and 54 staging of disease severity include lung function and hyper-responsiveness tests. 55 Sometimes fractional exhaled nitric oxide (FeNO) is used as a surrogate for direct 56 measurement of eosinophils. Improvement of clinical symptoms following 57 therapeutic intervention and assessment of atopy and a history of wheeze are also 58 useful.

59 Monitoring of the disease is generally through symptom assessment and therapeutic

60 dose requirements combined with periodic lung function tests. Novel approaches,

such as immunotherapy, have identified the utility of additional biomarkers such as

62 IgE or sputum inflammatory cell counts as inclusion criteria; however, in clinical

63 practice, often the principal read-outs remain the generalised clinical ones. No

single test provides definitive evidence of asthma, its severity or therapeutic efficacyof drugs.

66 Recent reports identified multiple disease phenotypes using unbiased clustering of

67 genomic and proteomic data from airway samples². Likewise, mRNA signatures of

68 severe asthma have been identified in whole blood ³. The importance of such studies

69 may be confounded by known changes in inflammatory cell profiles in asthma, thus,

70 missing changes in blood cell-subtypes by defining the phenotypic clusters of

71 subjects based on inflammatory cell predominance in biofluids.

72 Our approach was to gene expression markers of cell type and asthma in four

73 peripheral blood cell populations. We recruited 11 severe allergic asthmatics on step

4 of BTS/Sign management, and 10 healthy control subjects (see Table 1 for a

summary of patient characteristics). Participants signed written informed consent.

76 Table 1. Clinical characteristics for the healthy and moderate/severe allergic

77 asthmatic cohorts.

	Healthy controls	Severe allergic asthmatics	p value
Ν	10	11	-
Gender (M/F)	3/7	3/8	-
Age	42.5 (31-53)	43 (31-50)	0.87
Atopy (yes)	0	11	-
Total blood IgE	16.45 (10.7-27.8)	163.9 (71.4-315.0)	0.0003***
Blood lymphocytes	1.9 (1.75-2.125)	1.9 (1.7-2.1)	0.345
Blood eosinophils (%)	0.1 (0.1-0.2)	0.2 (0.1-0.3)	0.212
Pre FEV1	3.11 (2.89-4.13)	2.58 (2.15-3.49)	0.043*
Pre FEV1 % predicted	111.4 (105.3-117.1)	100 (77.2-102.4)	0.016*
Post FEV1	3.19 (3.04-4.19)	3.00 (2.37-3.66)	0.067
Post FEV1 % predicted	114.1 (107.7-119.4)	100.6 (86.2-114.7)	0.055
Sputum eosinophils (%)	0	1.69 (0-3.68)	0.046*
Sputum neutrophils (%)	11.36 (7.1-15.7)	64.46 (21.9-74.2)	0.006**
PBMC CD4+ (% of CD3+)	65.9 (53.5-71.2)	70.3 (58.5-78.5)	0.251
PBMC CD8+ (% of CD3+)	26.7 (18.6-33.0)	23.9 (16.8-26.5)	0.340
PBMC monocytes (% of CD45+)	11.7 (10.2-16.4)	12.8 (8.7-14.0)	0.878
PBMC NK cells (% of Cd45+)	11.1 (8.8-19.5)	10.6 (7.4-11.7)	0.314

Mann Whitney tests, *p<0.05, **p<0.01, ***p<0.001 Data shown are medians (+/- interquartile range)

78

Fresh blood was drawn and PBMCs were isolated from buffy coats. Flow cytometry
determined no significant differences in the relative proportions of four immune cell
populations, monocytes, NK cells, CD4+ and CD8+ T cells in the peripheral blood of
healthy and severe asthmatic subjects (Table 1).
Four cell populations were sequentially enriched from 4 x 10⁷ PBMCs from each

84 subject using magnetic beads conjugated to monoclonal antibodies targeting

- different cell surface markers, namely CD14 (monocytes), CD56 (NK/NK-T cells),
- 86 CD8 (CD8+ T cells), and CD4 (CD4+ T cells) in that order. This yielded populations
- 87 highly enriched (>99%) for each selective marker.
- 88 Quantification of gene expression used isolated RNA from the four enriched cell
- 89 populations, analysed by a 770 gene nCounter pan cancer immune profiling array
- 90 (NanoString Technologies).
- 91 Unbiased principal component analysis (PCA) of the purified cell gene expression
- 92 profiles robustly separated the four target cell populations (Figure 1A). The genes
- 93 primarily driving cluster separation of each cell type, and as such indicative of cell-
- 94 specific biomarkers, confirm the purity of our immune blood cell populations and add
- 95 to the canon of knowledge on markers of these cell types (see online data
- 96 supplement for cell-specific gene lists:
- 97 <u>https://doi.org/10.6084/m9.figshare.19329068</u>).
- 98 For example, a major component of the monocyte cluster was CD14, which was to
- 99 be expected since it was the target isolation molecule, but also includes 425 other
- 100 genes contributing to this cluster, inclusive of the well-characterised monocyte-
- 101 specific proteins such as CD68, CD163, L-selectin and S100A12.
- 102 T cells exhibit a well-defined cluster, however a small degree of overlap between the
- 103 CD4+ and CD8 + T cell clusters, reflects the phenotypic similarity between these two
- 104 cell types. Their combined cluster includes CD3 and CD8.
- 105 Similarly, our top-ranked genes contributing to the NK cell cluster are well-known
- 106 phenotypic markers of NK cells, inclusive of KLRD1, NCAM-1 and EOMES.
- 107 Clusters were driven primarily by cell type. We found little evidence of segregation
- 108 between health and asthma in these cell populations.
- 109 We then identified differentially expressed genes (DEGs) in asthma, adjusting for
- 110 multiple tests for each cell type as appropriate. Volcano plots (Figure 1B) indicate
- 111 two genes upregulated in asthmatic monocytes compared to healthy controls (IGF2R
- and C3AR1). IGF2R is upregulated in monocytes during differentiation into
- 113 macrophages ⁴ but changes in IGF2R expression by monocytes in asthma have not
- 114 previously been observed. C3AR1 has been previously identified as a susceptibility

gene for bronchial asthma ⁵. To our knowledge, no previous studies have identified
elevation of the C3AR1 in monocytes of severe asthmatics.

- 117 We found six upregulated (LILRA5, LILRB2 and SLC11A1, PDGFRB, LYN, CD97)
- 118 and eight downregulated (LTB, RORC, GZMK, DPP4, RPS6, FLT3LG, DOCK9 and
- 119 CD28) genes in CD56+ cells from asthmatics.

120 Several of these upregulated genes are associated with immune cell regulation. For

121 example, the leukocyte immunoglobulin-like immunoregulatory checkpoint receptors

122 LILRA5 and LILRB2 have both positive and negative regulatory properties, whereas

123 LYN-dependent signalling is primarily a negative regulator of innate and adaptive

124 immune responses⁶. Additionally, the PDGF pathway has a well described local

125 airways role in asthma pathogenesis and airway remodelling. Increased systemic

126 levels of PDGF ligands in the serum of asthmatics have been previously observed,

127 however it has remained uncertain whether PDGF is a systemic biomarker of

asthma⁷. Our study suggests that PDGF-receptor expression may provide evidence

129 of systemic response to abnormal PDGF expression in asthma.

- 130 Another upregulated gene in asthmatic NK cells is involved in pathogen resistance;
- 131 SLC11A1 plays a role in divalent metal ion transport, promoting anti-microbial

132 pathogen responses. This protein is upregulated in local innate lymphocytic cell

- 133 subtypes in asthma, augmenting their activation and biasing towards a Th1 rather
- 134 than Th2 response. Abnormal SLC11A1 expression has previously been identified

135 in asthmatic sputum cells⁸, attributed to localised bacterial exposure. Systemic

136 changes in expression of SLC11A1 may reflect the disease severity and the

137 consequent neutrophilic phenotype of our severe asthma cohort. However, the

138 existence of SLC11A1 upregulation in the peripheral is suggestive of widespread

139 systemic innate cell dysfunction.

140 Conversely, several genes downregulated in CD56+ cells of asthmatics (LTB,

141 RORC, GZMK, DPP4, RPS6, FLT3LG, DOCK9 and CD28), are associated with

142 proinflammatory, functional, cell or activation responses in NK cells. For example,

143 Iymphotoxin beta is a pro-inflammatory TNF- α superfamily member, granzyme K is a

serine protease and component of cytotoxic granules in NK cells, and CD28 is a co-

145 stimulatory molecule for NK cells. Interestingly, DPP4, which plays a role in NK cell

146 activation ⁹ is one of the ligands of IGF2R which is elevated in monocytes and may





148

149 Figure 1. Differential gene expression analysis in RNA transcripts in severe

150 **asthma. (A)** PCA analysis of gene counts from all four cell types indicate clusters

151 corresponding to each cell type. (B) Volcano plots indicating genes significantly up or

- down regulated in severe asthma in each cell type (p-adjusted < 0.05). **(C)** Summary
- 153 of GO terms associated with differential gene expression in NK cells in asthma.

154 Pathway analysis using the differentially expressed genes in the NK cell-enriched

- 155 population (Figure 1C) confirmed that severe allergic asthma was associated with
- 156 upregulation of pathways involved in metabolism, divalent metal ion transport,
- 157 immune response inhibition, and immune regulation/tolerance, and with

158 downregulation of T cell activation and immune system development.

159 Overall, these data suggest that an increased tolerogenic environment accompanies

160 severe asthma, and NK cell dysfunctions that would impair the adaptive immune

- 161 response were observed that could reflect exhaustion or generalised impairment of
- these cells. In addition, they show enhanced anti-microbial responses in the absence
- 163 of recent exacerbation. Although NK and NK-like cells have been examined in
- 164 asthma, no fixed role for them has yet been assigned. Our study suggests that
- 165 further investigation of these cells is warranted.
- 166 Additionally, monocytes in asthma show increases in gene expression associated
- 167 with differentiation and chemotaxis. Thus, we find innate but not adaptive cell
- 168 phenotypic changes in peripheral blood cells from severe asthmatics.
- 169 Given the increasing interest in innate immunity and its role in antimicrobial
- 170 responses, these results suggest the value of further study of gene expression
- 171 changes at times of acute asthma exacerbations.
- 172 The findings presented herein may help to identify new therapeutic avenues for
- 173 severe asthma arising from innate immunity, and also may serve to identify new
- 174 gene candidates as useful cell type-specific biomarkers.

175 References

176 1. Holgate, S.T., et al. Asthma. Nat Rev Dis Primers 1, 15025 (2015).

177 2. Takahashi, K., *et al.* Sputum proteomics and airway cell transcripts of current
178 and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. *Eur*179 *Respir J* 51(2018).

Bigler, J., *et al.* A Severe Asthma Disease Signature from Gene Expression
 Profiling of Peripheral Blood from U-BIOPRED Cohorts. *Am J Respir Crit Care Med* 195, 1311-1320 (2017).

4. Ohradanova-Repic, A., *et al.* The mannose 6-phosphate/insulin-like growth
factor 2 receptor mediates plasminogen-induced efferocytosis. *J Leukoc Biol* 105,
519-530 (2019).

186 5. Hasegawa, K., *et al.* Variations in the C3, C3a receptor, and C5 genes affect
187 susceptibility to bronchial asthma. *Hum Genet* 115, 295-301 (2004).

Brown D, Trowsdale J, Allen R. The LILR Family: Modulators of Innate and
Adaptive Immune Pathways in Health and Disease. *Tissue Antigens* 64, 215–25
(2004)

191 7. Kardas,G., et al, Role of platelet-derived growth factor (PDGF) in asthma as
192 an immunoregulatory factor mediating airway remodelling and possible
193 pharmacological target. Front. Pharmacol. 11, 1-8 (2020)

194 8. Hedges JF, et al, Solute carrier 571 11A1 is expressed by innate lymphocytes
195 and augments their activation. J. Immunol. 190, 4263-4273 (2013)

196 9. Klemann, C., Wagner, L., Stephan, M. & von Horsten, S. Cut to the chase: a
197 review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune
198 system. *Clin Exp Immunol* 185, 1-21 (2016).

199